Massimo Radaelli

Chairman & CEO of Noventia Pharma. He founded Noventia Pharma, a dynamic privately owned European Specialty Pharma Company with its H.Q. in Italy.

Dr. Radaelli is also Executive Chairman and a Shareholder of Pint Pharma Group, a company he founded in June 2012 to target Rare Diseases, Oncology and Hemoderivatives in Latin American. Pint He is based in Switzerland and Austria with subsidiaries in Argentina, Brazil, Colombia, Mexico, Ecuador, Peru, Chile, Venezuela and Central America Countries.

Dr. Radaelli is the CEO of Ferrer Italia, a J. V. company he founded in June 2016 to target Immune-in allergic diseases in Italy and Malta. Ferrer is engaged in the research, development, production and marketing of Vaccines in the Respiratory and Dermatology sector. Ferrer Acquired BioAllergologica in 2016 which has its Company HQ’s based in Rome Italy.

From 1996 until 2009 he was President & CEO of Dompé International based in Lausanne, Switzerland, assuming also responsibility for all of Dompé Pharma Italian operations. He was also co-founder of the Dupont-Merck JV Italian Subsidiary where he was Marketing & Medical Director. Dr Radaelli held various Sales & Marketing and Strategic Marketing position from 1982 to 1991 during his tenure in Hoffman La Roche and Menarini

He currently serves as a Board member of:

Pint Pharma Group a leading Specialty Pharma in LatAm focused Rare Diseases, Oncology, Hematology and Hemoderivatives;

Bioakos Pharma Labs a Specialty Pharma Italian Company with a Commercial Focus in Cardiology and Pain Management- Therapeutic areas with its HQ in Florence Italy;

Cytovia Threapeutics, a Global Immuno-Oncology company developing life-changing treatments for a variety of cancers, with a primary focus on blood cancers

He served also as a Member of the Board of Directors of Ariad Pharmaceuticals a leading US Biopharmaceutical Company focused on development and commercialization of biological therapeutics in severe Oncology diseases, Novabay a biopharmaceutical company focused on developing its proprietary and patented broad-spectrum, fast-acting, synthetic anti-infectives and Philogen a leading European Biotech Company focused on Oncology. IDRI (Infectious Diseases Research Institute), a non profit organization focus on Neglected Diseases based in Seattle;